Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan 13;1(1):CD013767.
doi: 10.1002/14651858.CD013767.pub2.

Foetal haemoglobin inducers for reducing blood transfusion in non-transfusion-dependent beta-thalassaemias

Wai Cheng Foong  1 , C Khai Loh  2 , Jacqueline J Ho  1 , Doris Sc Lau  2
Affiliations

Foetal haemoglobin inducers for reducing blood transfusion in non-transfusion-dependent beta-thalassaemias

Wai Cheng Foong et al. Cochrane Database Syst Rev. .

Abstract

Background: Non-transfusion-dependent β-thalassaemia (NTDβT) is a subset of inherited haemoglobin disorders characterised by reduced production of the β-globin chain of haemoglobin leading to anaemia of varying severity. Although blood transfusion is not a necessity for survival, it may be required to prevent complications of chronic anaemia, such as impaired growth and hypercoagulability. People with NTDβT also experience iron overload due to increased iron absorption from food sources which becomes more pronounced in those requiring blood transfusion. People with a higher foetal haemoglobin (HbF) level have been found to require fewer blood transfusions, thus leading to the emergence of treatments that could increase its level. HbF inducers stimulate HbF production without altering any gene structures. Evidence for the possible benefits and harms of these inducers is important for making an informed decision on their use.

Objectives: To compare the effectiveness and safety of the following for reducing blood transfusion for people with NTDβT: 1. HbF inducers versus usual care or placebo; 2. single HbF inducer with another HbF inducer, and single dose with another dose; and 3. combination of HbF inducers versus usual care or placebo, or single HbF inducer.

Search methods: We used standard, extensive Cochrane search methods. The latest search date was 21 August 2022.

Selection criteria: We included randomised controlled trials (RCTs) or quasi-RCTs comparing single HbF inducer with placebo or usual care, with another single HbF inducer or with a combination of HbF inducers; or comparing different doses of the same HbF inducer.

Data collection and analysis: We used standard Cochrane methods. Our primary outcomes were blood transfusion and haemoglobin levels. Our secondary outcomes were HbF levels, the long-term sequelae of NTDβT, quality of life and adverse events.

Main results: We included seven RCTs involving 291 people with NTDβT, aged two to 49 years, from five countries. We reported 10 comparisons using eight different HbF inducers (four pharmacological and four natural): three RCTs compared a single HbF inducer to placebo and seven to another HbF inducer. The duration of the intervention lasted from 56 days to six months. Most studies did not adequately report the randomisation procedures or whether and how blinding was achieved. HbF inducer against placebo or usual care Three HbF inducers, HQK-1001, Radix Astragali or a 3-in-1 combined natural preparation (CNP), were compared with a placebo. None of the comparisons reported the frequency of blood transfusion. We are uncertain whether Radix Astragali and CNP increase haemoglobin at three months (mean difference (MD) 1.33 g/dL, 95% confidence interval (CI) 0.54 to 2.11; 1 study, 2 interventions, 35 participants; very low-certainty evidence). We are uncertain whether Radix Astragali and CNP have any effect on HbF (MD 12%, 95% CI -0.74% to 24.75%; 1 study, 2 interventions, 35 participants; very low-certainty evidence). Only medians on haemoglobin and HbF levels were reported for HQK-1001. Adverse effects reported for HQK-1001 were nausea, vomiting, dizziness and suprapubic pain. There were no prespecified adverse effects for Radix Astragali and CNP. HbF inducer versus another HbF inducer Four studies compared a single inducer with another over three to six months. Comparisons included hydroxyurea versus resveratrol, hydroxyurea versus thalidomide, hydroxyurea versus decitabine and Radix Astragali versus CNP. No study reported our prespecified outcomes on blood transfusion. Haemoglobin and HbF were reported for the comparison Radix Astragali versus CNP, but we are uncertain whether there were any differences (1 study, 24 participants; low-certainty evidence). Different doses of the same HbF inducer Two studies compared two different types of HbF inducers at different doses over two to six months. Comparisons included hydroxyurea 20 mg/kg/day versus 10 mg/kg/day and HQK-1001 10 mg/kg/day, 20 mg/kg/day, 30 mg/kg/day and 40 mg/kg/day. Blood transfusion, as prespecified, was not reported. In one study (61 participants) we are uncertain whether the lower levels of both haemoglobin and HbF at 24 weeks were due to the higher dose of hydroxyurea (haemoglobin: MD -2.39 g/dL, 95% CI -2.80 to -1.98; very low-certainty evidence; HbF: MD -10.20%, 95% CI -16.28% to -4.12%; very low-certainty evidence). The study of the four different doses of HQK-1001 did not report results for either haemoglobin or HbF. We are not certain if major adverse effects may be more common with higher hydroxyurea doses (neutropenia: risk ratio (RR) 9.93, 95% CI 1.34 to 73.97; thrombocytopenia: RR 3.68, 95% CI 1.12 to 12.07; very low-certainty evidence). Taking HQK-1001 20 mg/kg/day may result in the fewest adverse effects. A combination of HbF inducers versus a single HbF inducer Two studies compared three combinations of two inducers with a single inducer over six months: hydroxyurea plus resveratrol versus resveratrol or hydroxyurea alone, and hydroxyurea plus l-carnitine versus hydroxyurea alone. Blood transfusion was not reported. Hydroxyurea plus resveratrol may reduce haemoglobin compared with either resveratrol or hydroxyurea alone (MD -0.74 g/dL, 95% CI -1.45 to -0.03; 1 study, 54 participants; low-certainty evidence). We are not certain whether the gastrointestinal disturbances, headache and malaise more commonly reported with hydroxyurea plus resveratrol than resveratrol alone were due to the interventions. We are uncertain whether hydroxyurea plus l-carnitine compared with hydroxyurea alone may increase mean haemoglobin, and reduce pulmonary hypertension (1 study, 60 participants; very low-certainty evidence). Adverse events were reported but not in the intervention group. None of the comparisons reported the outcome of HbF.

Authors' conclusions: We are uncertain whether any of the eight HbF inducers in this review have a beneficial effect on people with NTDβT. For each of these HbF inducers, we found only one or at the most two small studies. There is no information on whether any of these HbF inducers have an effect on our primary outcome, blood transfusion. For the second primary outcome, haemoglobin, there may be small differences between intervention groups, but these may not be clinically meaningful and are of low- to very low-certainty evidence. Data on adverse effects and optimal doses are limited. Five studies are awaiting classification, but none are ongoing.

Trial registration: ClinicalTrials.gov NCT00790127 NCT00809042 NCT01549080 NCT04411082.

PubMed Disclaimer

Conflict of interest statement

WCF: is involved in the management of people with non‐transfusion‐dependent thalassaemia and has received small pharmaceutical grants to attend conferences, all of which were unrelated to any HbF inducers.

CKL: is involved in the management of people with non‐transfusion‐dependent thalassaemia and has received small pharmaceutical grants to attend conferences, all of which were unrelated to any HbF inducers.

JJH: none.

DL: is involved in the management of people with non‐transfusion‐dependent thalassaemia and has received small pharmaceutical grants to attend conferences, all of which were unrelated to any HbF inducers.

Figures

1
1
2
2
3
3
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
1.1
1.1. Analysis
Comparison 1: Single HbF inducer at any dose or duration compared with usual care or placebo, Outcome 1: Mean haemoglobin (g/dL) at 3 months postintervention, subgroup by types of HbF inducer
1.2
1.2. Analysis
Comparison 1: Single HbF inducer at any dose or duration compared with usual care or placebo, Outcome 2: Mean HbF (%) at 3 months, subgroup by types of HbF inducer
2.1
2.1. Analysis
Comparison 2: Single HbF inducer at any dose or duration compared with another HbF inducer, Outcome 1: Mean haemoglobin (g/dL), subgroup by types of HbF inducer
2.2
2.2. Analysis
Comparison 2: Single HbF inducer at any dose or duration compared with another HbF inducer, Outcome 2: Mean HbF (%), subgroup by type of HbF inducer
3.1
3.1. Analysis
Comparison 3: One dose or dose regimen of a HbF inducer compared with another dose or dose regimen of the same HbF inducer: hydroxyurea 20 mg/kg/day versus hydroxyurea 10 mg/kg/day, Outcome 1: Mean haemoglobin (g/dL)
3.2
3.2. Analysis
Comparison 3: One dose or dose regimen of a HbF inducer compared with another dose or dose regimen of the same HbF inducer: hydroxyurea 20 mg/kg/day versus hydroxyurea 10 mg/kg/day, Outcome 2: Mean HbF (%)
3.3
3.3. Analysis
Comparison 3: One dose or dose regimen of a HbF inducer compared with another dose or dose regimen of the same HbF inducer: hydroxyurea 20 mg/kg/day versus hydroxyurea 10 mg/kg/day, Outcome 3: Major adverse effects (at 24 weeks)
4.1
4.1. Analysis
Comparison 4: Two or more HbF inducers at any dose or duration compared with usual care, placebo or a single HbF inducer, Outcome 1: Mean haemoglobin (g/dL) at 6 months postintervention, subgroup by types of HbF inducer
See this image and copyright information in PMC

Update of

  • doi: 10.1002/14651858.CD013767

Similar articles

See all similar articles

Cited by

References

References to studies included in this review

Bohara 2014 {published data only}
    1. Bohara VV, Raut L, Bardarkhe G, Pujari G, Chakrabarti P, Ray S, et al. Optimizing the dose of hydroxyurea in thalassemia intermedia. Indian Journal Hematology Blood Transfusion 2012;28(4):191-256. [CFGD REGISTER: TH143b]
    1. Bohara VV, Ray S, Chakrabarti P, Ray SS, Nath UK, Chaudhuri U. Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E- β-thalassemia): a single center study from Eastern India. Hemoglobin 2014;38(1):44-8. [CFGD REGISTER: TH143a] [PMID: ] - PubMed
Fucharoen 2013 {published data only}
    1. Fuchareon S, Inati AC, Siritanaratkul N, Koussa S, Taher A, Boosalis MS, et al. HQK-1001 is well tolerated and augments hemoglobin F and hemoglobin levels in patients with beta thalassemia intermedia. Blood 2010;116(21):4280. [CFGD REGISTER: TH113b] [DOI: 10.1182/blood.V116.21.4280.4280] - DOI
    1. Fucharoen S, Inati A, Siritanaratku N, Thein SL, Wargin WC, Koussa S, et al. A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia. British Journal of Haematology 2013;161(4):587-93. [CFGD REGISTER: TH113a] [PMID: ] - PMC - PubMed
Haghpanah 2018 {published data only}
    1. Comparison of the efficacy and safety of herbal product (Resveratrol) with hydroxyurea (HU) in non- transfusion- dependent B-thalassemia intermedia. en.irct.ir/trial/17784 (first registered 19 August 2015). [IRANIAN REGISTER OF CLINICAL TRIALS: IRCT2014112320051N2]
    1. Haghpanah S, Zarei T, Eshghi P, Zekavat O, Bordbar M, Hoormand M, et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Annals of Hematology 2018;97(10):1919-24. [CFGD REGISTER: TH180a] [PMID: ] - PubMed
    1. Karimi M, Haghpanah S, Zarei T, Eshgi P, Bordbar M, Zekavat O. Efficacy and safety of resveratrol, an oral HbF augmenting agent, in patients with beta thalassemia intermedia. Hemasphere 2018;2(S1):336. [CENTRAL: CN-01792057] [CFGD REGISTER: TH180b] - PubMed
Jain 2019 {published data only}
    1. Jain M, De R, Jitani A, Chakrabarti P, Mondal PK, Baul S, et al. Efficacy of thalidomide and hydroxyurea as HB F inducer in non-transfusion dependent thalassemia. Indian Journal of Hematology and Blood Transfusion 2019;35:S54. [ABSTRACT NO.: 42] [CFGD REGISTER: TH202] [DOI: 10.1007/s12288-019-01207-5] - DOI
Jha 2019 {published data only}
    1. Jha K, Ray R, Bhattacharyya M. Decitabine vs hydroxyurea on hemoglobin F induction in patients of E beta thalassemia. Indian Journal of Hematology & Blood Transfusion 2019;35(1):S52. [CFGD REGISTER: TH203]
Karimi 2010a {published data only}
    1. Karimi M, Mohammadi F, Behmanesh F, Samani SM, Borzouee M, Amoozgar H, et al. Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. European Journal of Haematology 2010;84(1):52-8. [CFGD REGISTER: TH125] [PMID: ] - PubMed
    1. NCT00809042. Combination therapy of hydroxyurea with L-carnitine and magnesium chloride in thalassemia intermedia [The effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of β-thalassemia intermedia patients]. clinicaltrials.gov/ct2/show/NCT00809042 (first received 16 December 2008).
Lu 2012 {published data only}
    1. Lu Z, Qian X, Zhang C, Chen Z, Du G. Radix astragali stimulates p38 MARK phosphorylation in pediatric patients with beta-thalassemia. Evidence-based Complementary and Alternative Medicine 2016;2016:7468979. [CFGD REGISTER: TH123b] [DOI: 10.1155/2016/7468979] - DOI - PMC - PubMed
    1. Lu ZM, Qian XH, Chen ZW, Zhang CH, Guo LS, Chen J. Prospective clinical study of radix astragali and its compound prescription for treatment of β-thalassemia in children. Zhongguo Dang Dai Er Ke Za Zhi (Chinese Journal of Contemporary Pediatrics) 2012;14(5):344-9. [CGD REGISTER: TH123] [PMID: ] - PubMed

References to studies excluded from this review

Biswas 2014 {published data only}
    1. Biswas S, Chaudhuri S, Kumar M, Sen A, Bhattyacharyya M, Ghosh K. The role of hydroxyurea and valproic acid in the management of severe HbE- β thalassaemia. Indian Journal of Hematology and Blood Transfusion 2014;30(Suppl 2):S505. [CFGD REGISTER: TH144]
Chai 2005 {published data only}
    1. Chai LM, Wu ZK, Zhang XH, Cai H. Effect of yisuishengxue granule on gene expression in children with beta-thalassemia. Zhongguo Zhong Xi Yi Jie He Za Zhi 2005;25(7):591-4. [ISSN 1003-5370] - PubMed
Cheng 2016 {published data only}
    1. Cheng YL, Zhang XH, Sun YW, Wang WJ, Fang SP, Wu ZK. Clinical effect and mechanism of Yisui Shengxue granules in thalassemia patients with mild, moderate, or severe anemia. Evidence-based Complementary Alternative Medicine 2016;2016:1713897. [DOI: 10.11155/2016/1713897] - DOI - PMC - PubMed
Elalfy 2013 {published data only}
    1. Elalfy MS, Adly AA, Ismail EA, Elhenawy YI, Elghamry IR. Therapeutic superiority and safety of combined hydroxyurea with recombinant human erythropoietin over hydroxyurea in young β-thalassemia intermedia patients. European Journal of Haematology 2013;91(6):522-33. [PMID: ] - PubMed
Fang 2007 {published data only}
    1. Fang S, Wu Z, Zhang X, Liu Y, Wang W, Chai L, et al. Clinical observation on YiSuiShengXue Granule on treating 156 patients with beta-thalassemia major and the molecular mechanism study. Biological & Pharmaceutical Bulletin 2007;30(11):2084-7. [DOI: 10.11248/bpb.30.2084] - DOI - PubMed
Guo 2014 {published data only}
    1. Guo L, Qian X, Zhao D, Lu Z, Chen J, Wu Q, et al. Radix astragali induces in vitro and in vivo synthesis of fetal hemoglobin in non‑transfusion‑dependent β‑thalassemia: a preliminary study. Molecular Medicine Reports 2014;Withdrawn. [DOI: 10.3892/mmr.2014.2856] [TRIAL ID: ChiCTR-TRC-13003672] - DOI - PubMed
Li 2016 {published data only}
    1. Li Y, He H, Yang L, Li X, Li D, Luo S. Therapeutic effect of Colla corii asini on improving anemia and hemoglobin compositions in pregnant women with thalassemia. International Journal of Hematology 2016;104(5):559-65. [PMID: ] - PubMed
    1. NCT02772016. Therapeutic effect of colla corii asini on improving anemia and hemoglobin composition in pregnant women with thalassemia. clinicaltrials.gov/ct2/show/NCT02772016 (first received 13 May 2016). - PubMed
Loukopoulos 1998 {published data only}
    1. Loukopoulos D, Voskaridou E, Stamoulakatou A, Papassotiriou Y, Kalotychou V, Loutradi A, et al. Hydroxyurea therapy in thalassemia. Annals of the New York Academy of Sciences 1998;850(1):120-8. [DOI: 10.1111/j.1749-6632.1998.tb10469.x] [PMID: ] - DOI - PubMed
Patthamalai 2014 {published data only}
    1. Patthamalai P, Fuchareon S, Chaneiam N, Ghalie RG, Chui DH, Boosalis MS, et al. A phase 2 trial of HQK-1001 in HbE-β thalassemia demonstrates HbF induction and reduced anemia. Blood 2014;123(12):1956-7. [DOI: 10.1182/blood-2013-11-538470] - DOI - PMC - PubMed

References to studies awaiting assessment

Cheng 2019 {published data only}
    1. Cheng YL, Zhang XH, Sun YW, Wang WJ, Huang J, Chu NL, et al. Genomewide DNA methylation responses in patients with β-thalassemia treated with Yisui Shengxue granules (YSSXG). Chinese Journal of Integrative Medicine 2019;25(7):490-6. [PMID: ] - PubMed
    1. NCT01549080. Study of effects of YisuiShengxue granules on thalassemia (thalessemia) [A double-blind, placebo-controlled, randomized, parallel-group study of the safety and effects of yisuishengxue granules on thalassemia presenting the syndrome of deficiency of liver/kidney-yin, and asthenia of essence/blood]. clinicaltrials.gov/show/NCT01549080 (first received 8 March 2012).
Huang 2016 {published data only}
    1. Huang L, Yao HX. Curative effects of hydroxyurea on the patients with β-thalassaemia intermadia. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2016;24(3):806-9. [PMID: ] - PubMed
Jain 2021 {published data only}
    1. Jain M, Chakrabarti P, Dolai TK, Ghosh P, Mandal PK, Baul SN, et al. Comparison of efficacy and safety of thalidomide vs hydroxyurea in patients with Hb E-beta thalassemia – a pilot study from a tertiary care centre of India. Blood Cells, Molecules & Diseases 2021;88:102544. [PMID: ] - PubMed
NCT04411082 {published data only (unpublished sought but not used)}
    1. NCT04411082. A phase 2 study to evaluate the safety and tolerability of IMR-687 in subjects with beta thalassemia. clinicaltrials.gov/ct2/show/NCT04411082 (first received 2 June 2020).
Wu 2007 {published data only}
    1. Wu ZK, Liu YM, Zhang XH, Liu WJ, Li M, Wang RX. Treatment of beta-thalassemia with Bushen Yisui therapy: a randomized controlled trial. Zhong Xi Yi Jie He Xue Bao (Journal of Chinese Integrative Medicine) 2007;5(2):137-40. [PMID: ] - PubMed

Additional references

Aerbajinai 2007
    1. Aerbajinai W, Zhu J, Gao Z, Chin K, Rodgers GP. Thalidomide induces gamma-globin gene expression through increased reactive oxygen species-mediated p38MAPK signaling and histone H4 acetylation in adult erythropoiesis. Blood 2007;110(8):2864-71. [DOI: 10.1182/blood-2007-01-065201] [PMID:17620452; PMCID: PMC2018668] - DOI - PMC - PubMed
Algiraigri 2017
    1. Algiraigri AH, Wright NA, Paolucci EO, Kassam A. Hydroxyurea for non transfusion-dependent β-thalassemia: a systematic review and meta-analysis. Hematology/Oncology and Stem Cell Therapy 2017;10(3):116-25. [DOI: 10.1016/j.hemonc.2017.02.002] - DOI - PubMed
Amoozgar 2011
    1. Amoozgar H, Farhani N, Khodadadi N, Karimi M, Cheriki S. Comparative study of pulmonary circulation and myocardial function in patients with β-thalassemia intermedia with and without hydroxyurea, a case-control study. European Journal of Haematology 2011;87(1):61-7. [PMID: ] - PubMed
Ansari 2019
    1. Ansari SH, Lassi ZS, Khowaja SM, Adil S, Shamsi TS. Hydroxyurea (hydroxycarbamide) for transfusion-dependent β-thalassaemia. Cochrane Database of Systematic Reviews 2019, Issue 3. Art. No: CD012064. [DOI: 10.1002/14651858.CD012064.pub2] - DOI - PMC - PubMed
Asadov 2018
    1. Asadov C, Alimirzoeva Z, Mammadova T, Aliyeva G, Gafarova S, Mammadov J. Beta-thalassemia intermedia: a comprehensive overview and novel approaches. International Journal of Hematology 2018;108(1):5-21. [DOI: 10.1007/s12185-018-2411-9] - DOI - PubMed
Baliga 2000
    1. Baliga BS, Pace BS, Chen HH, Shah AK, Yang YM. Mechanism for fetal hemoglobin induction by hydroxyurea in sickle cell erythroid progenitors. American Journal of Hematology 2000;65(3):227-33. [DOI: 10.1002/1096-8652(200011)65:3<227::aid-ajh9>3.0.co;2-v] [PMID: ] - DOI - PubMed
Bianchi 2009
    1. Bianchi N, Zuccato C, Lampronti I, Borgatti M, Gambari R. Fetal hemoglobin inducers from the natural world: a novel approach for identification of drugs for the treatment of β-thalassemia and sickle-cell anemia. Evidence-Based Complementary and Alternative Medicine: eCAM 2009;6(2):141-51. [DOI: 10.1093/ecam/nem139] - DOI - PMC - PubMed
Borgna‐Pignatti 2007
    1. Borgna-Pignatti C. Modern treatment of thalassaemia intermedia. British Journal of Haematology 2007;138(3):291-304. [PMID: ] - PubMed
Botzenhardt 2018
    1. Botzenhardt S, Felisi M, Bonifazi D, Del Vecchio GC, Putti MC, Kattamis A, et al. Long-term safety of deferiprone treatment in children from the Mediterranean region with beta-thalassemia major: the DEEP-3 multi-center observational safety study. Haematologica 2018;103(1):e1-4. [PMID: ] - PMC - PubMed
Bradai 2003
    1. Bradai M, Abad MT, Pissard S, Lamraoui F, Skopinski L, Montalembert M. Hydroxyurea can eliminate transfusion requirements in children with severe β-thalassemia. Blood 2003;102(4):1529-30. - PubMed
Bradai 2007
    1. Bradai M, Pissard S, Abad MT, Dechartres A, Ribeil JA, Landais P, et al. Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia. Transfusion 2007;47(10):1830-6. [PMID: ] - PubMed
Camaschella 1995
    1. Camaschella C, Cappellini MD. Thalassemia intermedia. Haematologica 1995;80(1):58-68. [PMID: ] - PubMed
Cao 1996
    1. Cao A, Galanello R, Rosatelli MC, Argiolu F, De Virgiliis S. Clinical experience of management of thalassemia: the Sardinian experience. Seminars in Hematology 1996;33(1):66-75. - PubMed
Cappellini 2006
    1. Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 2006;107(9):3455-62. - PubMed
Carrocini 2011
    1. Carrocini GC, Zamaro PJ, Bonini-Domingos CR. What influences Hb fetal production in adulthood? Revista Brasiliera de Hematologica e Hemoterapia 2011;33(3):231-6. [DOI: 10.5581/1516-8484.20110059] - DOI - PMC - PubMed
Casu 2018
    1. Casu C, Nemeth E, Rivella S. Hepcidin agonists as therapeutic tools. Blood 2018;131(16):1790-4. [DOI: 10.1182/blood-2017-11-737411] - DOI - PMC - PubMed
Charache 1992
    1. Charache S, Dover GJ, Moore RD, Eckert S, Ballas SK, Koshy M, et al. Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia. Blood 1992;79(10):2555-65. [PMID: ] - PubMed
Cheng 2016
    1. Cheng YL, Zhang XH, Sun YW, Wang WJ, Fang SP, Wu ZK. Clinical effect and mechanism of Yisui Shengxue granules in thalassemia patients with mild, moderate, or severe anemia. Evidence-Based Complementary and Alternative Medicine 2016;2016:1713897. [DOI: 10.1155/2016/1713897] [PMID: ] - DOI - PMC - PubMed
Deeks 2022
    1. Deeks JJ, Higgins JP, Altman DG. Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.
De Sanctis 2017
    1. De Sanctis V, Kattamis C, Canatan C, Soliman AT, Elsedfy H, Karimi M, et al. β-thalassemia distribution in the old world: an ancient disease seen from a historical standpoint. Mediterranean Journal of Hematology and Infectious Diseases 2017;9(1):e2017018. - PMC - PubMed
DeSimone 2002
    1. DeSimone J, Koshy M, Dorn L, Lavelle D, Bressler L, Molokie R, et al. Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia. Blood 2002;99(1):3905-8. [DOI: 10.1182/blood.v99.11.3905] [PMID: 12010787] - DOI - PubMed
El‐Beshlawy 2014
    1. El-Beshlawy A, El-Ghamrawy M, EL-Ela MA, Said F, Adolf S, Abdel-Razek AR, et al. Response to hydroxycarbamide in pediatric β-thalassemia intermedia: 8 years' follow-up in Egypt. Annals of Hematology 2014;93(12):2045-50. [PMID: ] - PubMed
Elbourne 2002
    1. Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9. - PubMed
Fang 2007
    1. Fang S, Wu Z, Zhang X, Liu Y, Wang W, Chai L, et al. Clinical observation on YiSuiShengXue Granule on treating 156 patients with beta-thalassemia major and the molecular mechanism study. Biological & Pharmaceutical Bulletin 2007;30(11):2084-7. [DOI: 10.1248/bpb.30.2084] [PMID:17978480] - DOI - PubMed
Fard 2013
    1. Fard AD, Hosseini SA, Shahjahani M, Salari F, Jaseb K. Evaluation of novel fetal hemoglobin inducer drugs in treatment of β-hemoglobinopathy disorders. International Journal of Hematology, Oncology and Stem Cell Research 2013;7(3):47-54. - PMC - PubMed
Fisher 2013
    1. Fisher SA, Brunskill SJ, Doree C, Gooding S, Chowdhury O, Roberts DJ. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia. Cochrane Database of Systematic Reviews 2013, Issue 8. Art. No: CD004450. [DOI: 10.1002/14651858.CD004450.pub3] [PMID: ] - DOI - PMC - PubMed
Fucharoen 1996
    1. Fucharoen S, Siritanaratkul N, Winichagoon P, Chowthaworn J, Siriboon W, Muangsup W, et al. Hydroxyurea increases hemoglobin F levels and improves the effectiveness of erythropoiesis in beta-thalassemia/hemoglobin E disease. Blood 1996;87(3):887-92. [PMID: ] - PubMed
Gamberini 2004
    1. Gamberini MR, Fortini M, De Sanctis V. Healing of leg ulcers with hydroxyurea in thalassaemia intermedia patients with associated endocrine complications. Pediatric Endocrinology Reviews 2004;2(Suppl 2):319-22. [PMID: ] - PubMed
GRADEpro GDT [Computer program]
    1. GRADEpro GDT. Hamilton (ON): McMaster University (developed by Evidence Prime), accessed prior to 7 March 2022. Available from gradepro.org.
Guerrini 2009
    1. Guerrini A, Lampronti I, Bianchi N, Zuccato C, Breveglieri G, Salvatori F, et al. Bergamot (Citrus bergamia Risso) fruit extracts as gamma-globin gene expression inducers: phytochemical and functional perspectives. Journal of Agricultural and Food Chemistry 2009;57(10):4103-11. [PMID: ] - PubMed
Higgins 2003
    1. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60. - PMC - PubMed
Higgins 2017
    1. Higgins JP, Altman DG, Sterne JA. Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). Cochrane, 2017. Available from training.cochrane.org/handbook/archive/v5.2.
Higgins 2022
    1. Higgins JP, Eldridge S, Li T, editor(s). Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.
Hoppe 1999
    1. Hoppe C, Vichinsky E, Lewis B, Foote D, Styles L. Hydroxyurea and sodium phenylbutyrate therapy in thalassemia intermedia. American Journal of Hematology 1999;62(4):221-7. - PubMed
Italia 2009
    1. Italia KY, Jijina FJ, Merchant R, Panjwani S, Nadkarni AH, Sawant PM, et al. Response to hydroxyurea in beta thalassemia major and intermedia: experience in western India. Clinica Chimica Acta: International Journal of Clinical Chemistry 2009;407(1-2):10-5. [DOI: 10.1016/j.cca.2009.06.019] - DOI - PubMed
Kalantri 2018
    1. Kalantri SA, Ray R, Chattopadhyay A, Bhattacharjee S, Biswas A, Bhattacharyya M. Efficacy of decitabine as haemoglobin F inducer in HbE/β-thalassemia. Annals of Hematology 2018;97(9):1689-94. [DOI: 10.1007/s00277-018-3357-y] - DOI - PubMed
Karimi 2010b
    1. Karimi M, Cohan N, Mousavizadeh K, Falahi MJ, Haghpanah S. Adverse effects of hydroxyurea in β-thalassaemia intermedia patients: 10 years' experience. Pediatric Hematology and Oncology 2010;27(3):205-11. [DOI: 10.3109/08880011003639952] - DOI - PubMed
Kinney 1999
    1. Kinney TR, Helms RW, O'Branski EE, Ohene-Frempong K, Wang W, Daeschner C, et al. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Blood 1999;94(5):1550-4. [PMID: ] - PubMed
Kohne 2010
    1. Kohne E, Kleihauer E. Hemoglobinopathies: a longitudinal study over four decades. Deutsches Arzteblatt International 2010;107(5):65-71. [PMID: ] - PMC - PubMed
Kohne 2011
    1. Kohne E. Hemoglobinopathies: clinical manifestations, diagnosis, and treatment. Deutsches Arzteblatt International 2011;108(31-2):532-40. [PMID: ] - PMC - PubMed
Kosaryan 2014
    1. Kosaryan M, Karami H, Zafari M, Yaghobi N. Report on patients with non transfusion-dependent beta-thalassemia major being treated with hydroxyurea attending the Thalassemia Research Center, Sari, Mazandaran Province, Islamic Republic of Iran in 2013. Hemoglobin 2014;38(2):115-8. [PMID: ] - PubMed
Kumari 2011
    1. Kumari S, Mishra A, Tiwari A. Beta-thalassemia treatment passing through natural fetal hemoglobin inducers. Journal of Pharmacy Research 2011;4(9):3851-5.
Lefebvre 2022
    1. Lefebvre C, Glanville J, Briscoe S, Littlewood A, Marshall C, Metzendorf MI, et al. Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.
Li 2011
    1. Li H, Ko CH, Tsang SY, Leung PC, Fung MC, Fung KP. The ethanol extract of fructus trichosanthis promotes fetal hemoglobin production via p38 MAPK activation and ERK inactivation in K562 cells. Evidence-Based Complementary and Alternative Medicine: eCAM 2011;2011:657056. [DOI: 10.1093/ecam/neq022] [PMID: ] - DOI - PMC - PubMed
Li 2022
    1. Li T, Higgins JP, Deeks JJ. Chapter 5: Collecting data. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.
Lu 2016
    1. Lu Z, Qian X, Zhang C, Chen Z, Du G. Radix Astragali stimulates p38MARK phosphorylation in pediatric patients with β-thalassemia. Evidence-Based Complementary and Alternative Medicine 2016;2016:7468979. [DOI: 10.1155/2016/7468979] [PMID: 27882072; PMCID: PMC5110864] - DOI - PMC - PubMed
Mallery 1991
    1. Mallery JA, Gardin JM, King SW, Ey S, Henry WL. Effects of heart rate and pulmonary artery pressure on doppler pulmonary artery acceleration time in experimental acute pulmonary hypertension. Chest 1991;100:470-3. [DOI: 10.1378/chest.100.2.470] - DOI - PubMed
Mancuso 2006
    1. Mancuso A, Maggio A, Renda D, Di Marzo R, Rigano P. Treatment with hydroxycarbamide for intermedia thalassaemia: decrease of efficacy in some patients during long-term follow up. British Journal of Haematology 2006;133(1):105-6. [PMID: ] - PubMed
Meo 2008
    1. Meo A, Cassinerio E, Castelli R, Bignamini D, Perego L, Cappellini MD. Effect of hydroxyurea on extramedullary haematopoiesis in thalassaemia intermedia: case reports and literature review. International Journal of Laboratory Hematology 2008;30(5):425-31. [PMID: ] - PubMed
Migliaccio 2008
    1. Migliaccio AR, Rotili D, Nebbioso A, Atweh G, Mai A. Histone deacetylase inhibitors and hemoglobin F induction in β-thalassemia. International Journal of Biochemistry & Cell Biology 2008;11(40):2341-7. [DOI: 10.1016/j.biocel.2008.04.024] - DOI - PMC - PubMed
Modell 2008
    1. Modell B, Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. Bulletin of the World Health Organization 2008;86(6):480-7. [PMID: ] - PMC - PubMed
MOH China 1995
    1. Ministry of Health of the People's Republic of China. Guiding principle of clinical research on new drugs (Part 2). Ministry of Health, China 1995:137-8.
Musallam 2012
    1. Musallam KM, Sankaran VG, Cappellini MD, Duca L, Nathan DG, Taher AT. Fetal hemoglobin levels and morbidity in untransfused patients with beta-thalassemia intermedia. Blood 2012;119(2):364-7. [DOI: 10.1182/blood-2011-09-382408] - DOI - PubMed
Musallam 2013a
    1. Musallam KM, Taher AT, Cappellini MD, Sankaran VG. Clinical experience with fetal hemoglobin induction therapy in patients with b-thalassemia. Blood 2013;121(12):2199-212. - PubMed
Musallam 2013b
    1. Musallam KM, Rivella S, Vichinsky E, Rachmilewitz AE. Non-transfusion-dependent thalassemias. Haematologica 2013;98(6):833-44. [DOI: 10.3324/haematol.2012.066845] - DOI - PMC - PubMed
Nemeth 2009
    1. Nemeth E, Ganz T. The role of hepcidin in iron metabolism. Acta Haematologica 2009;122(2-3):78-86. [DOI: 10.1159/000243791] - DOI - PMC - PubMed
Ng 2014
    1. Ng NY, Ko CH. Natural remedies for the treatment of beta-thalassemia and sickle cell anemia-current status and perspectives in fetal hemoglobin reactivation. International Scholarly Research Notices 2014;2014:123257. [PMID: ] - PMC - PubMed
Nuinoon 2010
    1. Nuinoon M, Makarasara W, Mushiroda T, Setianingsih I, Wahidiyat PA, Sripichai O, et al. A genome-wide association identified the common genetic variants influence disease severity in beta-thalassemia/hemoglobin E. Human Genetics 2010;127(3):303-14. [PMID: ] - PubMed
Olivieri 2011
    1. Olivieri NF, Saunthararajah Y, Thayalasuthan V, Kwiatkowski J, Ware RE, Kuypers FA, et al. A pilot study of subcutaneous decitabine in β-thalassemia. Blood 2011;118(10):2708-11. - PMC - PubMed
Origa 2007
    1. Origa R, Galanello R, Ganz T, Giagu N, Maccioni L, Faa G, et al. Liver iron concentrations and urinary hepcidin in beta-thalassemia. Haematologica 2007;92(5):583-8. [DOI: 10.3324/haematol.10842] - DOI - PubMed
Pace 2002
    1. Pace BS, White GL, Dover GJ. Short-chain fatty acid derivatives induce fetal globin expression and erythropoiesis in vivo. Blood 2002;100(13):4640-8. [DOI: 10.1182/blood-2002-02-0353] - DOI - PMC - PubMed
Page 2022
    1. Page MJ, Higgins JP, Sterne JA. Chapter 13: Assessing risk of bias due to missing results in a synthesis. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.
Patthamalai 2014
    1. Patthamalai P, Fuchareon S, Chaneiam N, Ghalie RG, Chui DH, Boosalis MS, et al. A phase 2 trial of HQK-1001 in HbE-β thalassemia demonstrates HbF induction and reduced anemia. Blood 2014;123(12):1956-7. - PMC - PubMed
Pearson 1967
    1. Pearson HA. Life-span of the fetal red blood cell. Journal of Pediatrics 1967;70(2):166-71. [DOI: 10.1016/s0022-3476(67)80410-4] - DOI - PubMed
Pekala 2011
    1. Pekala J, Patkowska-Sokoła B, Bodkowski R, Jamroz D, Nowakowski P, Lochyński S, et al. L-carnitine – metabolic functions and meaning in humans life. Current Drug Metabolism 2011;12(7):667-78. [DOI: 10.2174/138920011796504536] [PMID:21561431] - DOI - PubMed
Perrine 1989
    1. Perrine SP, Miller BA, Faller DV, Cohen RA, Vichinsky EP, Hurst D, et al. Sodium butyrate enhances fetal globin gene expression inerythroid progenitors of patients with Hb SS and beta thalassemia. Blood 1989;74(1):454-9. [PMID: 2473801] - PubMed
Perrine 2011
    1. Perrine SP, Wargin WA, Boosalis MS, Wallis WJ, Case S, Keefer JR, et al. Evaluation of safety and pharmacokinetics of sodium 2,2 dimethylbutyrate, a novel short chain fatty acid derivative, in a phase 1, double-blind, placebo-controlled, single-dose, and repeat-dose studies in healthy volunteers. Journal of Clinical Pharmacology 2011;51(8):1186-94. [PMID: ] - PMC - PubMed
Pippard 1979
    1. Pippard MJ, Callender ST, Warner GT, Weatherall DJ. Iron absorption and loading in beta-thalassaemia intermedia. Lancet 1979;2(8147):819-21. [PMID: ] - PubMed
Pourfarzad 2013
    1. Pourfarzad F, Lindern M, Azarkeivan A, Hou J, Kia SK, Esteghamat F, et al. Hydroxyurea responsiveness in β-thalassemic patients is determined by the stress response adaptation of erythroid progenitors and their differentiation propensity. Haematologica 2013;98(5):696-704. [DOI: 10.3324/haematol.2012.074492] - DOI - PMC - PubMed
Rankine‐Mullings 2022
    1. Rankine-Mullings AE, Nevitt SJ. Hydroxyurea (hydroxycarbamide) for sickle cell disease. Cochrane Database of Systematic Reviews 2022, Issue 9. Art. No: CD002202. [DOI: 10.1002/14651858.CD002202.pub3] - DOI - PMC - PubMed
Reid 2014
    1. Reid ME, El Beshlawy A, Inati A, Kutlar A, Abboud MR, Haynes J Jr, et al. A double-blind, placebo-controlled phase II study of the efficacy and safety of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease. American Journal of Hematology 2014;89(7):709-13. - PubMed
Ren 2018
    1. Ren Q, Zhou YL, Wang L, Chen YS, Ma YN, Li PP, et al. Clinical trial on the effects of thalidomide on hemoglobin synthesis in patients with moderate thalassemia intermedia. Annals of Hematology 2018;97(10):1933-9. [DOI: 10.1007/s00277-018-3395-5] [PMID: 29931453.] - DOI - PubMed
Review Manager 2014 [Computer program]
    1. Review Manager (RevMan 5). Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Rigano 2010
    1. Rigano P, Pecoraro A, Calzolari R, Troia A, Acuto S, Renda D, et al. Desensitization to hydroxycarbamide following long-term treatment of thalassaemia intermedia as observed in vivo and in primary erythroid cultures from treated patients. British Journal of Haematology 2010;151(5):509-15. [PMID: ] - PubMed
Rodrigue 2001
    1. Rodrigue CM, Arous N, Bachir D, Smith-Ravin J, Romeo PH, Galacteros F, et al. Resveratrol, a natural dietary phytoalexin, possesses similar properties to hydroxyurea towards erythroid differentiation. British Journal of Haematology 2001;113(2):500-7. [DOI: 10.1046/j.1365-2141.2001.02746.x] - DOI - PubMed
Rodriguez 1998
    1. Rodriguez GI, Kuhn JG, Weiss GR, Hilsenbeck SG, Eckardt JR, Thurman A, et al. A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea. Blood 1998;91(5):1533-41. [DOI: 10.1182/blood.V91.5.1533] - DOI - PubMed
Sankaran 2013
    1. Sankaran VG, Orkin SH. The switch from fetal to adult hemoglobin. Cold Spring Harbour Perspective Medicine 2013;3(1):a011643. [DOI: 10.1101/cshperspect.a011643] - DOI - PMC - PubMed
Schünemann 2022a
    1. Schünemann HJ, Vist GE, Higgins JP, Santesso N, Deeks JJ, Glasziou P, et al. Chapter 15: Interpreting results and drawing conclusions. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.
Schünemann 2022b
    1. Schünemann HJ, Higgins JP, Vist GE, Glasziou P, Akl EA, Skoetz N, et al. Chapter 14: Completing 'Summary of findings' tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.
Selby 1997
    1. Selby R, Nisbet-Brown E, Basran RK, Chang L, Olivieri NF. Valproic acid and augmentation of fetal hemoglobin in individuals with and without sickle cell disease. Blood 1997;90(2):891-2. - PubMed
Sharma 2019
    1. Sharma A, Easow Mathew M, Puri L. Splenectomy for people with thalassaemia major or intermedia. Cochrane Database of Systematic Reviews 2019, Issue 9. Art. No: CD010517. [DOI: 10.1002/14651858.CD010517.pub3] - DOI - PMC - PubMed
Shearstone 2016
    1. Shearstone JR, Golonzhka O, Chonkar A, Tamang D, Duzer JH, Jones SS, et al. Chemical inhibition of histone deacetylases 1 and 2 induces fetal hemoglobin through activation of GATA2. PLOS One 2016;11(4):e0153767. [DOI: 10.1371/ journal.pone.0153767] - PMC - PubMed
Shen 1986
    1. Shen ZY, Wang WJ. Reference criteria for differentiation of deficiency syndromes in traditional Chinese medicine. Journal of Integrated Traditional Chinese and Western Medicine 1986;6(10):598.
Singer 2005a
    1. Singer ST, Kuypers FA, Olivieri NF, Weatherall DJ, Mignacca R, Coates TD, et al. Single and combination drug therapy for fetal hemoglobin augmentation in hemoglobin E-beta 0-thalassemia: considerations for treatment. Annals of the New York Academy of Sciences 2005;1054:250-6. - PubMed
Singer 2005b
    1. Singer ST, Kuypers FA, Olivieri NF, Weatherall DJ, Mignacca R, Coates TD, et al. Fetal haemoglobin augmentation in E/beta(0) thalassaemia: clinical and haematological outcome. British Journal of Haematology 2005;131(3):378-88. [PMID: ] - PubMed
Steinberg 2010
    1. Steinberg MH, McCarthy WF, Castro O, Ballas SK, Armstrong FD, Smith W, et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. American Journal of Hematology 2010;85(6):403-8. [DOI: 10.1002/ajh.21699] - DOI - PMC - PubMed
Strouse 2012
    1. Strouse JJ, Heeney MM. Hydroxyurea for the treatment of sickle cell disease: efficacy, barriers, toxicity, and management in children. Pediatric Blood Cancer 2012;59(2):365-71. [PMID: ] - PMC - PubMed
Taher 2009
    1. Taher AT, Musallam KM, Cappellini MD. Thalassaemia intermedia: an update. Mediterranean Journal of Hematology and Infectious Diseases 2009;1(1):e2009004. [PMID: ] - PMC - PubMed
Taher 2010
    1. Taher AT, Musallam KM, Karimi M, El-Beshlawy A, Belhoul K, Daar S, et al. Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. Blood 2010;115(10):1886-92. [PMID: ] - PubMed
Taher 2021
    1. Taher AT, Cappellini MD. Luspatercept for β-thalassemia: beyond red blood cell transfusions. Expert Opinion on Biological Therapy 2021;21(11):1363-71. [DOI: 10.1080/14712598.2021.1968825] - DOI - PubMed
TIF 2018a
    1. Taher A, Musallam K, Cappellini MD. Chapter 2: Blood transfusion. In: Taher A, Musallam K, Cappellini MD, editors(s). Guidelines for Management of Non Transfusion Dependent Thalassemia (NTDT). 2nd edition. Nicosia (Cyprus): Thalassaemia International Federation, 2018:14-20. [ISBN: 978-9963-717-11-8]
TIF 2018b
    1. Taher A, Musallam K, Cappellini MD. Chapter 4: Splenectomy. In: Taher A, Musallam K, Cappellini MD, editors(s). Guidelines for Management of Non Transfusion Dependent Thalassemia (NTDT). 2nd edition. Nicosia, Cyprus: Thalassaemia International Federation, 2018:30-8. [ISBN: 978-9963-717-11-8]
Uda 2008
    1. Uda M, Galanello R, Sanna S, Lettre G, Sankaran VG, Chen W, et al. Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of beta-thalassemia. Proceedings of the National Academy of Sciences of the United States of America 2008;105(5):1620-5. [DOI: 10.1073/pnas.0711566105] - DOI - PMC - PubMed
Wagner 2002
    1. Wagner CT, Martowicz ML, Livesey SA, Connor J. Biochemical stabilization enhances red blood cell recovery and stability following cryopreservation. Cryobiology 2002;45:153-66. [DOI: 10.1016/S0011-2240(02)00124-4] - DOI - PubMed
Wang 2009
    1. Wang WJ, Wu ZK, Zhang XH, Wang RX, Liu YM, Fang SP, et al. Observations on after-effect duration of kidney-nourishing and marrow-replenishing therapy on 58 cases of Mediterranean anemia. Journal of Traditional Chinese Medicine (Chung i Tsa Chih Ying Wen Pan) 2009;29(4):258-62. [PMID: ] - PubMed
Weatherall 2001
    1. Weatherall DJ. The Thalassaemia Syndrome. 4th edition. Hoboken (NJ): Blackwell Science, 2001.
Weatherall 2012
    1. Weatherall DJ. The definition and epidemiology of non-transfusion-dependent thalassemia. Blood Reviews 2012;26(Suppl 1):S3-6. [DOI: 10.1016/S0268-960X(12)70003-6] - DOI - PubMed
WHO 2012
    1. World Health Organization. The World Health Organization Quality of Life (WHOQOL). www.who.int/mental_health/publications/whoqol/en/ (accessed 8 October 2020).
Witt 2003
    1. Witt O, Mönkemeyer S, Rönndahl G, Erdlenbruch B, Reinhardt D, Kanbach K, et al. Induction of fetal hemoglobin expression by the histone deacetylase inhibitor apicidin. Blood 2003;101(5):2001-7. [DOI: 10.1182/blood-2002-08-2617] - DOI - PubMed
World Bank 2021
    1. World Bank. World Bank country and lending groups. datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-coun... (accessed prior to 7 March 2022).
Yank 1999
    1. Yank V, Rennie D. Disclosure of researcher contributions: a study of original research articles in The Lancet. Annals of Internal Medicine 1999;130(8):661-70. [DOI: 10.7326/0003-4819-130-8-199904200-00013] - DOI - PubMed
Zhang 2007
    1. Zhang ZN, Shen T. Standard of Diagnosis and Therapeutic Effect of Hematopathy. Beijing (China): Science Press, 2007.
Zheng 2002
    1. Zheng XY. In: Guiding Principle of Clinical Research on Chinese New Herbal Medicines. Beijing (China): Chinese Medicine Science and Technology Press, 2002:173-84.
Zimmerman 2004
    1. Zimmerman SA, Schultz WH, Davis JS, Pickens CV, Mortier NA, Howard TA, et al. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood 2004;103(6):2039-45. [PMID: ] - PubMed

References to other published versions of this review

Foong 2015
    1. Foong WC, Ho JJ, Loh CK, Viprakasit V. Hydroxyurea for reducing blood transfusion in non-transfusion dependent beta thalassaemias. Cochrane Database of Systematic Reviews 2015, Issue 3. Art. No: CD011579. [DOI: 10.1002/14651858.CD011579] - DOI - PMC - PubMed
Foong 2016
    1. Foong WC, Ho JJ, Loh CK, Viprakasit V. Hydroxyurea for reducing blood transfusion in non-transfusion dependent beta thalassaemias. Cochrane Database of Systematic Reviews 2016, Issue 10. Art. No: CD011579. [DOI: 10.1002/14651858.CD011579.pub2] - DOI - PMC - PubMed

Publication types

Associated data

LinkOut - more resources